{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:24:01Z","timestamp":1785813841687,"version":"3.56.0"},"reference-count":80,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["2020J05264"],"award-info":[{"award-number":["2020J05264"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["2023J011210"],"award-info":[{"award-number":["2023J011210"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Planning Project of Fujian Provincial Health Commission","award":["2020GGA002"],"award-info":[{"award-number":["2020GGA002"]}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2022QNA003"],"award-info":[{"award-number":["2022QNA003"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec019\">\n<jats:title>Background<\/jats:title>\n<jats:p>Evidence supports the long-term efficacy of Nucleos(t)ide Analogs (NAs) therapy in improving chronic hepatitis B (CHB) prognosis. However, determining the most cost-effective first-line NAs remains unclear. China\u2019s implementation of the New Volume-Based Procurement Policy (NVBP Policy) in 2019 led to substantial price reductions for entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF). This study assesses the cost-effectiveness of ETV, TDF, and TAF, both with and without NVBP, for CHB in China.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec020\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A state-transition model, parameterized using data from published literature, was utilized to compare treatment strategies encompassing non-NAs best support care (BSC), ETV, TDF, and TAF, with or without NVBP. A simulated lifetime cohort was employed, measuring outcomes such as predicted liver-related deaths, costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec021\">\n<jats:title>Results<\/jats:title>\n<jats:p>In comparison to Non-NAs BSC, TAF yielded an additional 2.68 QALYs per person, with an ICER of 7,853.22 USD\/QALY. Subsequently, TDF generated an additional 2.61 QALYs\/person at an ICER of 7,153.39 USD\/QALY, and ETV produced an additional 2.01 QALYs\/person with an ICER of 9,366.74 USD\/QALY without NVBP. Incorporating NVBP, the ICERs for TAF, TDF, and ETV decreased to \u2212745.62 USD\/QALY, \u2212729.33 USD\/QALY, and \u2212871.11 USD\/QALY, respectively, compared to non-NAs BSC. At willingness-to-pay (WTP) thresholds ranging from 12,500 USD\/QALY to 37,500 USD\/QALY, TAF with NVBP showed an increased probability (51.15\u201352.47%) of being the optimal treatment strategy, followed by TDF and ETV with NVBP exhibiting a reduced likelihood 43.09\u201342.45% and 6.40\u20134.48% in the iterations.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec022\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our analysis suggests that TAF with NVBP represents the most cost-effective long-term therapy for CHB. Both TDF and ETV, with or without NVBP, and TAF without NVBP were considered cost-ineffective.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0327298","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:26:34Z","timestamp":1752254794000},"page":"e0327298","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Tenofovir alafenamide is superior to tenofovir disoproxil fumarate and entecavir in cost-effectiveness of treatment of chronic hepatitis B in china with new volume-based procurement policy"],"prefix":"10.1371","volume":"20","author":[{"given":"Yi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3936-8010","authenticated-orcid":true,"given":"Shiyun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"3","key":"pone.0327298.ref001","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jhep.2020.09.013","article-title":"A global investment framework for the elimination of hepatitis B","volume":"74","author":"J Howell","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"pone.0327298.ref002","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1186\/s12879-019-4428-y","article-title":"Hepatitis B infection in the general population of China: a systematic review and meta-analysis","volume":"19","author":"H Wang","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0327298.ref003","first-page":"1","article-title":"Burden of cirrhosis and other chronic liver diseases caused by specific etiologies in China, 1990-2016: findings from the global burden of disease study 2016","volume":"33","author":"M Li","year":"2020","journal-title":"Biomed Environ Sci"},{"issue":"6","key":"pone.0327298.ref004","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/hep.27406","article-title":"The global burden of liver disease: the major impact of China","volume":"60","author":"F-S Wang","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"pone.0327298.ref005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"NA Terrault","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"pone.0327298.ref006","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"M Omata","year":"2017","journal-title":"Hepatol Int"},{"issue":"1","key":"pone.0327298.ref007","first-page":"3","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version2022","volume":"41","author":"Chinese Society of Hepatology CMACSoID","year":"2023","journal-title":"). Chin J Clin Infect Dis"},{"key":"pone.0327298.ref008","volume-title":"Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection","author":"WHO Guidelines Approved by the Guidelines Review Committee","year":"2015"},{"issue":"3","key":"pone.0327298.ref009","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Y-F Liaw","year":"2012","journal-title":"Hepatol Int"},{"issue":"2","key":"pone.0327298.ref010","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1073\/pnas.0307422100","article-title":"Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy","volume":"101","author":"J Summers","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pone.0327298.ref011","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/liv.12401","article-title":"HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?","author":"M Vigan\u00f2","year":"2014","journal-title":"Liver Int"},{"issue":"12","key":"pone.0327298.ref012","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/liv.13253","article-title":"Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients","volume":"36","author":"T-H Su","year":"2016","journal-title":"Liver Int"},{"issue":"2","key":"pone.0327298.ref013","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5009\/gnl18546","article-title":"Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis b patients: a systematic review and meta-analysis","volume":"14","author":"X Wang","year":"2020","journal-title":"Gut Liver"},{"issue":"10","key":"pone.0327298.ref014","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/jgh.15078","article-title":"Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: a systematic review","volume":"35","author":"C-H Tseng","year":"2020","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"pone.0327298.ref015","article-title":"Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries","volume":"18","author":"J-L Hou","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"pone.0327298.ref016","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jhep.2018.01.031","article-title":"Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population","volume":"68","author":"GV Papatheodoridis","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"pone.0327298.ref017","doi-asserted-by":"crossref","first-page":"13537","DOI":"10.1038\/s41598-020-70433-z","article-title":"Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate","volume":"10","author":"Y Ha","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0327298.ref018","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","article-title":"Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic hbv infection: a systematic review and meta-analysis","volume":"19","author":"W-M Choi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"pone.0327298.ref019","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12072-019-10005-0","article-title":"Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis","volume":"14","author":"M Li","year":"2020","journal-title":"Hepatol Int"},{"issue":"1","key":"pone.0327298.ref020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study","volume":"5","author":"J Choi","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"pone.0327298.ref021","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"NA Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"pone.0327298.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"SK Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"3","key":"pone.0327298.ref023","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"GBD 2017 Cirrhosis Collaborators","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"pone.0327298.ref024","first-page":"860","article-title":"Cost-effectiveness of community-based treatment of chronic hepatitis B in China","volume":"38","author":"SX Zhang","year":"2017","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"issue":"4","key":"pone.0327298.ref025","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/hep.29922","article-title":"Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis","volume":"68","author":"L Xie","year":"2018","journal-title":"Hepatology"},{"issue":"19","key":"pone.0327298.ref026","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1097\/CM9.0000000000000445","article-title":"First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China","volume":"132","author":"X-R Yin","year":"2019","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"pone.0327298.ref027","first-page":"324","article-title":"3-year treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for chronic HBV infection in China","volume":"9","author":"J Hou","year":"2021","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"pone.0327298.ref028","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000519440","article-title":"Real-world single-center comparison of the safety and efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in patients with chronic hepatitis B","volume":"65","author":"S Jeong","year":"2022","journal-title":"Intervirology"},{"issue":"1","key":"pone.0327298.ref029","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1186\/s12913-022-07851-4","article-title":"Reevaluation of adverse drug reactions of psychiatric drugs under the chinese drug volume-based procurement policy","volume":"22","author":"Z Du","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"pone.0327298.ref030","author":"(NDA) TCNDA","year":"2016"},{"key":"pone.0327298.ref031"},{"key":"pone.0327298.ref032","unstructured":"The Prices of Drugs, Examination, and Test in Fujian Provincial Hospital. Accessed 2023 October 30."},{"issue":"2","key":"pone.0327298.ref033","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40273-019-00852-y","article-title":"Cost-effectiveness of tenofovir alafenamide for treatment of chronic hepatitis B in Canada","volume":"38","author":"F Tian","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"pone.0327298.ref034","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/liv.14848","article-title":"Nucleos(t)ide analogue therapy: the role of tenofovir alafenamide","author":"M Buti","year":"2021","journal-title":"Liver Int"},{"key":"pone.0327298.ref035"},{"key":"pone.0327298.ref036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","article-title":"Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China","volume":"24","author":"X Yue","year":"2021","journal-title":"Value Health Reg Issues"},{"issue":"5","key":"pone.0327298.ref037","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.34790","article-title":"Predictive factors in the incidence of cirrhosis in chronic hepatitis B virus infections","volume":"16","author":"SM Alavian","year":"2016","journal-title":"Hepat Mon"},{"issue":"6","key":"pone.0327298.ref038","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/MEG.0000000000000341","article-title":"Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients","volume":"27","author":"Z Poh","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"pone.0327298.ref039","doi-asserted-by":"crossref","first-page":"918017","DOI":"10.4061\/2011\/918017","article-title":"Treatment of hepatitis B in decompensated liver cirrhosis","volume":"2011","author":"R Guan","year":"2011","journal-title":"Int J Hepatol"},{"issue":"12","key":"pone.0327298.ref040","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1046\/j.1440-1746.2003.03187.x","article-title":"Chronic hepatitis B: a long-term retrospective cohort study of disease progression in Shanghai, China","volume":"18","author":"B Xu","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"pone.0327298.ref041","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-0676.1989.tb00405.x","article-title":"Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study","volume":"9","author":"YF Liaw","year":"1989","journal-title":"Liver"},{"issue":"3","key":"pone.0327298.ref042","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/cam4.1998","article-title":"Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment","volume":"8","author":"K Tarao","year":"2019","journal-title":"Cancer Med"},{"issue":"6","key":"pone.0327298.ref043","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1440-1746.2005.03813.x","article-title":"Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression","volume":"20","author":"X Lin","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0327298.ref044","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1365-2036.2010.04473.x","article-title":"The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study","volume":"32","author":"KM Fleming","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0327298.ref045","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"G Fattovich","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"pone.0327298.ref046","doi-asserted-by":"crossref","first-page":"20922","DOI":"10.1038\/s41598-020-77515-y","article-title":"Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States","volume":"10","author":"M Yang","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0327298.ref047","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2012.02.033","article-title":"Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy","volume":"57","author":"C-Y Peng","year":"2012","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0327298.ref048","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/BF02774306","article-title":"Ten year survival rate of 131 patients with liver cirrhosis excluded the association of liver carcinoma at the establishment of diagnosis","volume":"15","author":"I Okazaki","year":"1980","journal-title":"Gastroenterol Jpn"},{"issue":"5","key":"pone.0327298.ref049","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00004836-200205000-00018","article-title":"Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation","volume":"34","author":"AY Hui","year":"2002","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"pone.0327298.ref050","first-page":"15","article-title":"Epidemiology of hepatitis B virus infection in China: current status and challenges","volume":"2","author":"Y-P Yan","year":"2014","journal-title":"J Clin Transl Hepatol"},{"issue":"11","key":"pone.0327298.ref051","first-page":"508","article-title":"Incidence and mortality of liver cancer in China in 2011","volume":"34","author":"T-T Zuo","year":"2015","journal-title":"Chin J Cancer"},{"issue":"6","key":"pone.0327298.ref052","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6412","article-title":"Trends in characteristics, mortality, and other outcomes of patients with newly diagnosed cirrhosis","volume":"2","author":"ES Orman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"pone.0327298.ref053","first-page":"108","article-title":"The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis","volume":"19","author":"S Hassanipour","year":"2020","journal-title":"EXCLI J"},{"issue":"12","key":"pone.0327298.ref054","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1097\/TP.0000000000002246","article-title":"Recipient age and mortality after liver transplantation: a population-based cohort study","volume":"102","author":"E Gil","year":"2018","journal-title":"Transplantation"},{"issue":"3","key":"pone.0327298.ref055","article-title":"Recipient age and mortality risk after liver transplantation: a population-based cohort study","volume":"11","author":"H-P Chen","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"pone.0327298.ref056","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1365-182X(17)30625-1","article-title":"Causes of hospital death in patients undergoing liver transplantation","volume":"1","author":"ST Fan","year":"1999","journal-title":"HPB"},{"issue":"21","key":"pone.0327298.ref057","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3748\/wjg.v25.i21.2591","article-title":"Liver transplantation for hepatocellular carcinoma: where do we stand?","volume":"25","author":"F Santopaolo","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"5","key":"pone.0327298.ref058","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.26301","article-title":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis","volume":"58","author":"GL-H Wong","year":"2013","journal-title":"Hepatology"},{"issue":"12","key":"pone.0327298.ref059","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/jvh.12971","article-title":"Mortality, liver transplantation and hepatic complications in patients with treatment-na\u00efve chronic hepatitis B treated with entecavir vs tenofovir","volume":"25","author":"BG Kim","year":"2018","journal-title":"J Viral Hepat"},{"issue":"1","key":"pone.0327298.ref060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/infdis\/jiy391","article-title":"Reduced incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with Tenofovir-A propensity score-matched study","volume":"219","author":"MH Nguyen","year":"2019","journal-title":"J Infect Dis"},{"issue":"11","key":"pone.0327298.ref061","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/jvh.13601","article-title":"Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B","volume":"28","author":"HW Lee","year":"2021","journal-title":"J Viral Hepat"},{"issue":"9","key":"pone.0327298.ref062","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.15499","article-title":"Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis","volume":"50","author":"K Liu","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"pone.0327298.ref063","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000519440","article-title":"Real-world single-center comparison of the safety and efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in patients with chronic hepatitis B","volume":"65","author":"S Jeong","year":"2022","journal-title":"Intervirology"},{"issue":"11","key":"pone.0327298.ref064","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00535-020-01726-3","article-title":"Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?","volume":"55","author":"TC-F Yip","year":"2020","journal-title":"J Gastroenterol"},{"issue":"9","key":"pone.0327298.ref065","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1016\/j.transproceed.2018.03.061","article-title":"Cost analysis and determinants of living donor liver transplantation in Taiwan","volume":"50","author":"L-M Lin","year":"2018","journal-title":"Transplant Proc"},{"issue":"3","key":"pone.0327298.ref066","first-page":"324","article-title":"Pharmacoeconomic comparison of cyclosporine A and FK506 in liver transplant recipients (in Chinese)","volume":"26","author":"XTH Wang","year":"2006","journal-title":"Chin Hosp Pharm J"},{"issue":"1","key":"pone.0327298.ref067","first-page":"1","article-title":"Clinical study of treatment for end stage liver alveolar echinococcosis with ex-vivo liver resection and autologous liver transplantation","volume":"11","author":"HFX Ma","year":"2017","journal-title":"Chin J Transplant"},{"issue":"3","key":"pone.0327298.ref068","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/MLR.0b013e31820192cd","article-title":"Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making?: results from a study in patients with chronic prostatitis","volume":"49","author":"F-L Zhao","year":"2011","journal-title":"Med Care"},{"key":"pone.0327298.ref069"},{"issue":"9","key":"pone.0327298.ref070","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-005519","article-title":"Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China","volume":"6","author":"J Yuan","year":"2021","journal-title":"BMJ Glob Health"},{"key":"pone.0327298.ref071","unstructured":"(NMPA) CsNMPA. Center for Drug Evaluation Annual Report. 2022."},{"issue":"1","key":"pone.0327298.ref072","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41598-020-80523-7","article-title":"Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B","volume":"11","author":"T-S Chang","year":"2021","journal-title":"Sci Rep"},{"issue":"12","key":"pone.0327298.ref073","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/jvh.13384","article-title":"A multi-centre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy","volume":"27","author":"SU Kim","year":"2020","journal-title":"J Viral Hepat"},{"issue":"5","key":"pone.0327298.ref074","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4166\/kjg.2019.74.5.251","article-title":"Long term efficacy of antiviral therapy: mortality and incidence of hepatocellular carcinoma","volume":"74","author":"HW Lee","year":"2019","journal-title":"Korean J Gastroenterol"},{"issue":"3","key":"pone.0327298.ref075","first-page":"324","article-title":"3-year Treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for chronic HBV infection in China","volume":"9","author":"J Hou","year":"2021","journal-title":"J Clin Transl Hepatol"},{"issue":"4","key":"pone.0327298.ref076","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96\u00a0weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"K Agarwal","year":"2018","journal-title":"J Hepatol"},{"issue":"11","key":"pone.0327298.ref077","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1111\/jgh.14686","article-title":"Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate","volume":"34","author":"S Kaneko","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"pone.0327298.ref078","year":"2020"},{"key":"pone.0327298.ref079"},{"issue":"9","key":"pone.0327298.ref080","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.14309\/ajg.0000000000000651","article-title":"Prevalence of chronic hepatitis B virus infection in the United States","volume":"115","author":"JK Lim","year":"2020","journal-title":"Am J Gastroenterol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0327298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:26:48Z","timestamp":1752254808000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0327298"}},"subtitle":[],"editor":[{"given":"Yury E","family":"Khudyakov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":80,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0327298","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}